studia universitatis babeş-bolyai biologia 2

C. PAŞCA et al.
the treatment, aggravated progressively, but after 11 days started decreasing; at the
end of the 18 days of our experiment, an obvious recovery tendency was noticed,
all the modifications having a zonal character and affected especially isolated
myocytes and only a small number of groups of myocardial cells.
Conclusions. 1. A single therapeutic dose of 400 mg Carboplatin/m 2 body
surface has a moderate toxic effect on the rat myocardium consisting of the
appearance both of certain histological and ultrastructural modifications.
2. All the modifications induced by this anticancer drug seem to be due to
the grave circulatory disturbances and the thrombocytopenia.
3. Carboplatin determines certain histological alterations: capillary stasis,
interfascicular haemorrhages, oedemas, nuclear modifications (hypertrophy, the
presence of an increased number of nucleoli, a peculiar arrangement of the
chromatin in groups) and an obvious collagenous proliferation in the lysis areas.
4. The ultrastructural modifications induced by Carboplatin consist of cell
swelling, disorganisation of the cell ultrastructure, especially at the periphery of
the myocytes, lysis of the sarcolemma and myofibrils, breaking of the Z-lines,
swelling of the interfascicular spaces, swelling and degeneration of the mitochondria,
myocyte disorganisation and myolysis.
R E F E R E N C E S
1. B r e n d a, S. W., A Beginner’s Handbook in Biological Transmission Electron
Microscopy, Butler & Tanner, London,1981.
2. C a l v e r t, A. H., Dose optimisation of carboplatin in adults, "Anticancer Res.", 14,
1994, 2273-2278.
3. D i e t r i c h, W. S., The ultrastructure of cardiac muscle in health and disease,
"Micron", 24 (1), 1993, 47-73.
4. F l e c k e n s t e i n, A., J a n k e, J., D o r i n g, H. J., P a c h i n g e r, O., Calcium
overload as the determinant factor in the production of catecholamine-induced
myocardial lesions, "Cardiomyopathies", 2, 1973, 455-466.
5. G r i g g, A., S z e r, J., S k o v, K., B a r n e t t, M., Multi-organ dysfunction
associated with high-dose carboplatin therapy prior to autologous transplantation,
"Bone Marrow Transplantation", 17, 1996, 67-74.
6. H r u b a n, R. H., S t e r n b e r g, S. S., M e y e r s, P., F l e i s h e r, M., M e n e n d e z-
B o t e t, C., B o i t n o t t, J. K., Fatal thrombocytopenia and liver failure associated
with carboplatin therapy, "Cancer Invest.", 9(3), 1991, 263-268.
7. K a t z, A. M., F r e s t o n, J. W., M e s s i n e o, F. C., H e r b e t t e, L. G., Membrane
damage and the pathogenesis of cardiomyopathies, "J. Molec. Cell. Cardiol.", 17,
1985, 11-20.
54